HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
Saved in:
| Title: | HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases. |
|---|---|
| Authors: | Brun MK; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Bjørlykke KH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway., Viken MK; Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.; Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway., Stenvik GE; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Klaasen RA; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Gehin JE; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Warren DJ; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Sexton J; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Sandanger Ø; Section of Dermatology, Oslo University Hospital, Oslo, Norway., Kvien TK; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Mørk C; Akershus Dermatology Center, Lørenskog, Norway., Haavardsholm EA; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Jahnsen J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway., Goll GL; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Lie BA; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.; Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway., Bolstad N; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Jørgensen KK; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway., Syversen SW; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway. |
| Source: | Journal of internal medicine [J Intern Med] 2023 May; Vol. 293 (5), pp. 648-655. Date of Electronic Publication: 2023 Feb 26. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 8904841 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2796 (Electronic) Linking ISSN: 09546820 NLM ISO Abbreviation: J Intern Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
